Free Trial

Capricor Therapeutics Q4 2024 Earnings Report

Capricor Therapeutics logo
$9.06 -0.21 (-2.27%)
As of 04/4/2025 04:00 PM Eastern

Capricor Therapeutics EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Capricor Therapeutics Revenue Results

Actual Revenue
$11.13 million
Expected Revenue
$9.87 million
Beat/Miss
Beat by +$1.26 million
YoY Revenue Growth
N/A

Capricor Therapeutics Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

Capricor Therapeutics Earnings Headlines

Cantor Fitzgerald Brokers Lift Earnings Estimates for CAPR
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Check Out What Whales Are Doing With CAPR
See More Capricor Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Capricor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capricor Therapeutics and other key companies, straight to your email.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ:CAPR), Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

View Capricor Therapeutics Profile

More Earnings Resources from MarketBeat